Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

NCT03160885 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

794

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Tralokinumab
DRUG: Placebo

Sponsor

LEO Pharma